knowledge -WSS

knowledge

author：comprehensive 2025-09-30 23:04:16 - browse：9912

A person walks past the Palantir sign. -- health tech coverage from STAT — FABRICE COFFRINI/AFP via Getty Images

PALO ALTO, Calif. — At a bustling artificial intelligence conference in June hosted by data heavyweight Palantir, a handful of relative newcomers — hospital executives — milled among government and defense industry customers spiritedly trading new uses for the company’s automation and analytics services.

Palantir is best known for its work in government and intelligence, but early adopters of the company’s nascent health offerings, including leaders from Cleveland Clinic, Tampa General Hospital, and HCA, offered demos and gave keynotes last month explaining applications like sepsis monitoring or staff scheduling tools.

For the hospital systems, it’s an expensive bid to tailor the company’s AI technology to hospital operations — and an attempt to blunt the effects of severe staffing shortages and limited bed space amid a resurgence of in-person care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The EPA's new lead rule: How one expert crunched the numbers

WSS

STAT readers on older presidents, polypills, Medicare, and more

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Disappointing trial forces Pfizer to pivot on obesity medicine plans

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

He's a Nobel laureate. Critics say he was misleading on Covid

Alabama IVF ruling threatens families facing fatal genetic disease

focus

knowledge

Wikipedia

Sports medicine is finally prioritizing gender equality

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

What does generative AI mean for health care? We asked experts

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

BioMarin wins approval for gene therapy to treat hemophilia A

NIH study of ME/CFS points to clear biological hallmarks

Moonlake's readout produced a cash windfall. Risks remain

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

entertainment

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Diagnostic tests are hitting their mathematical limits

The Harvard botanist who searched for psychedelics in the Amazon

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Alabama frozen embryo ruling has major implications for IVF clinics

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Wikipedia

hotspot

explore

leisure time